Skip to main content
Equibles

Dana Pizzuti, M.D.

Crinetics Pharmaceuticals, Inc.

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Dana Pizzuti, M.D.

Crinetics Pharmaceuticals, Inc. reported in an 8-K filed October 3, 2022 that Dana Pizzuti, M.D. was appointed Chief Development Officer, effective September 30, 2022. Dana Pizzuti, M.D. has spoken on 1 earnings call across 1 company, most recently for Crinetics Pharmaceuticals, Inc. on May 8, 2025.

“On October 3, 2022, Crinetics Pharmaceuticals, Inc. (the "Company" or "Crinetics") announced the appointment of Dana Pizzuti, M.D. as the Company's Chief Development Officer, which was effective as of September 30, 2022.”
Crinetics Pharmaceuticals, Inc. Form 8-K, filed October 3, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • Crinetics Pharmaceuticals, Inc.

    SEC 8-K

    Current

    2022-09-30–present

Company network

Recorded roles and call appearances connecting this person to public companies.

Crinetics Pharmaceuticals, Inc.

Current role
1 appearance Latest appearance 2025-05-08

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

  • Earnings call

    Crinetics Pharmaceuticals, Inc. Q1 FY2025 Earnings Call

    Crinetics Pharmaceuticals, Inc.

  • Executive change Appointed: Chief Development Officer

    Crinetics Pharmaceuticals, Inc.